Treatment patterns of melanoma by BRAF mutation status in the USA from 2011 to 2017: a retrospective cohort study

Melanoma Management

Morganna L Freeman¹  Shweta Shah²  Leon Raskin³  David Cohan⁴  Omid Hamid⁵ 

[1] Research Institute, Los Angeles, CA, USA;1Global Health Economics, Amgen Inc., Thousand Oaks, CA, USA;2Center for Observational Research, Amgen Inc., Thousand Oaks, CA, USA;3Medical Affairs, Amgen Inc., Thousand Oaks, CA, USA;;4The Angeles Clinic &

关键词: BRAF status;    BRAF/MEK inhibitors;    checkpoint inhibitors;    melanoma;    retrospective study;    treatment patterns;   

DOI  :  10.2217/mmt-2019-0013

来源: DOAJ

【 摘 要 】

Aim: To describe treatment changes from 2011 to 2017 and demographic/clinical characteristics of patients with advanced melanoma who received systemic therapy by BRAF status. Patients & methods: Treatment patterns were evaluated in adults from the Oncology Services Comprehensive Electronic Records database who received antimelanoma systemic therapy. Results: Checkpoint inhibitors were prevailingly prescribed (66%); usage increased from 2011 (21%) to 2017 (84%). BRAF/MEK inhibitors were the second most common (21%); usage increased from 2011 (6%) to 2012 (18%) and stabilized until 2017 (22%). BRAF/MEK inhibitors (65%) and checkpoint inhibitors (57%) were predominantly used for BRAFMut melanoma. Conclusion: Overall, checkpoint inhibitors have supplanted other therapies for advanced melanoma. Treatment shifts have occurred for BRAFMut melanoma, notably increased use of checkpoint inhibitors and BRAF/MEK combinations compared with monotherapies.

【 授权许可】

Unknown